Brokers Set Expectations for Aurinia Pharmaceuticals Inc’s FY2017 Earnings (AUPH)
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) – Analysts at Cantor Fitzgerald dropped their FY2017 earnings estimates for shares of Aurinia Pharmaceuticals in a report issued on Monday. Cantor Fitzgerald analyst E. Piros now expects that the biotechnology company will post earnings per share of ($1.06) for the year, down from their previous forecast of ($1.01). Cantor Fitzgerald has a “Buy” rating and a $14.00 price objective on the stock. Cantor Fitzgerald also issued estimates for Aurinia Pharmaceuticals’ FY2018 earnings at ($0.76) EPS.
Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last announced its earnings results on Tuesday, November 14th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.14) by ($0.02). Aurinia Pharmaceuticals had a negative net margin of 18,089.02% and a negative return on equity of 25.56%. The business had revenue of $0.03 million for the quarter, compared to analyst estimates of $0.03 million. The firm’s quarterly revenue was up .0% on a year-over-year basis. WARNING: This news story was originally posted by Watch List News and is owned by of Watch List News. If you are accessing this news story on another publication, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this news story can be read at https://www.watchlistnews.com/brokers-set-expectations-for-aurinia-pharmaceuticals-incs-fy2017-earnings-auph/1721072.html.
Several other brokerages have also issued reports on AUPH. Vetr lowered Aurinia Pharmaceuticals from a “buy” rating to a “hold” rating and set a $6.64 target price on the stock. in a research report on Wednesday, September 6th. Seaport Global Securities reaffirmed a “buy” rating and set a $10.00 target price on shares of Aurinia Pharmaceuticals in a research report on Friday, October 6th. BidaskClub lowered Aurinia Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, July 28th. Zacks Investment Research raised Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 target price on the stock in a research report on Tuesday, August 15th. Finally, Leerink Swann upped their target price on Aurinia Pharmaceuticals from $10.00 to $14.00 and gave the company an “outperform” rating in a research report on Monday, October 23rd. Two research analysts have rated the stock with a sell rating, six have given a buy rating and one has assigned a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $10.79.
Aurinia Pharmaceuticals (NASDAQ:AUPH) opened at $5.27 on Wednesday. Aurinia Pharmaceuticals has a 1 year low of $2.02 and a 1 year high of $10.54.
Several hedge funds have recently made changes to their positions in the company. FMR LLC increased its holdings in shares of Aurinia Pharmaceuticals by 0.3% in the second quarter. FMR LLC now owns 5,867,800 shares of the biotechnology company’s stock valued at $35,969,000 after purchasing an additional 19,200 shares during the period. Vivo Capital LLC increased its holdings in shares of Aurinia Pharmaceuticals by 68.9% in the second quarter. Vivo Capital LLC now owns 1,013,149 shares of the biotechnology company’s stock valued at $6,211,000 after purchasing an additional 413,149 shares during the period. Goldman Sachs Group Inc. increased its holdings in shares of Aurinia Pharmaceuticals by 357.3% in the second quarter. Goldman Sachs Group Inc. now owns 876,461 shares of the biotechnology company’s stock valued at $5,373,000 after purchasing an additional 684,816 shares during the period. Alyeska Investment Group L.P. increased its holdings in shares of Aurinia Pharmaceuticals by 1.8% in the third quarter. Alyeska Investment Group L.P. now owns 681,517 shares of the biotechnology company’s stock valued at $4,273,000 after purchasing an additional 12,171 shares during the period. Finally, Balyasny Asset Management LLC increased its holdings in shares of Aurinia Pharmaceuticals by 66.7% in the second quarter. Balyasny Asset Management LLC now owns 500,000 shares of the biotechnology company’s stock valued at $3,065,000 after purchasing an additional 200,000 shares during the period. 27.66% of the stock is currently owned by institutional investors and hedge funds.
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.
Receive News & Ratings for Aurinia Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.